Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

265 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    NDRC Issued Opinions And Notice On Drug Price Reform

    On May 4, 2015, the National Development and Reform Commission ("NDRC") and seven agencies including the National Health and Family Planning Commission and the Ministry of Human Resources and Social Security jointly published Opinions on Promoting Drug Price Reform (the "Opinions").
    ChinaFood, Drugs, Healthcare, Life Sciences
    Sheppard
    Sheppard
  • Article

    试管婴儿辅助生殖行业法律问题探究

    近期关于试管婴儿代孕、代为供卵取卵以及同性之间试管婴儿抚养权归属等问题媒体新闻报道越来越多
    ChinaFood, Drugs, Healthcare, Life Sciences
    AnJie Broad Law Firm
    AnJie Broad Law Firm
Article

Chinese Food (Additive) Industry: Manufacturing Licence is Now Required

The Chinese General Administration of Quality Supervision, Inspection and Quarantine ("AQSIQ") published the Rules of Administration and Supervision on Production of Food Additives ("Rules") on 4 April 2010 (to be entered into force on 1 June 2010).
ChinaConsumer Protection
CMS Cameron McKenna Nabarro Olswang
CMS Cameron McKenna Nabarro Olswang
  • Article

    Llinks Corporate Compliance & Legal Alert

    The Supreme People's Court released the Interpretation on Several Issues Concerning the Application of the Company Law of the People's Republic of China (Draft for Comments).
    ChinaCorporate/Commercial Law
    Llinks Law Offices
    Llinks Law Offices
  • Article

    Growth and Opportunities in China's Medical Device Market.

    Overview of the development, segmentation, driving forces, and emerging opportunities within China's medical device market.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Acclime
    Acclime
  • Article

    Healthcare Public-Private Partnerships (PPP): Is There A Need For Bidding?

    As the government vigorously promotes cooperation between government and social capital in infrastructure and public services fields, interesting legal questions arise with respect to the operation of PPP projects.
    ChinaGovernment, Public Sector
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Study On Foreign-Invested Medical Institutions (I): Policies

    Can foreign investors set up wholly-owned medical institutions in China? This is a question that clients constantly ask when entering the Chinese healthcare industry...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    BIOSECURE Act: Anticipated Movement, Key Provisions, And Likely Impact

    Last night, the House of Representatives passed the BIOSECURE Act (BIOSECURE or the Act) by a bipartisan vote of 306 to 81.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Study On Foreign-Invested Medical Institutions (II): Case Studies

    As mentioned in Study on Foreign-Invested Medical Institutions (I), although China had at one time implemented a pilot program for establishing wholly foreign-owned hospitals, current policies prohibit full ownership.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Several Ways For Responding To Office Action Regarding Methods For Diagnosis And Treatment Of Diseases

    According to Article 25.3 of the Chinese Patent Law, a method for diagnosis and treatment of diseases shall not be granted for patent right.
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    61款创新医疗器械获批:2023年度中国医疗器械注册工作报告亮点解读

    在前一篇文章《60余款创新药获批:2022-2023年度中国药品审评报告亮点解读》中,我们对2022-2023年度药品审评报告中所体现的我国近两年药品注册与监管
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    汉坤 • 观点 | 医药BD项目如何友好"分手"?

    医药BD(business development,商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年,
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Understanding The EU's International Procurement Instrument

    Earlier this year, the Commission relied for the first time on the EU's International Procurement Instrument in order to take measures against China for its failure to ensure reciprocal access to public...
    ChinaGovernment, Public Sector
    Crowell & Moring LLP
    Crowell & Moring LLP
  • Article

    Comparative Analysis Of The First Tax Preferential Health Insurance Products (In Chinese)

    个人税收优惠型健康险(下称"税优健康险"),即能够享受个人所得税减免政策、由商业保险公司承保的健康险。
    ChinaInsurance
    AnJie Broad Law Firm
    AnJie Broad Law Firm
  • Article

    Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

    In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.
    ChinaIntellectual Property
    Rouse
    Rouse
  • Article

    Industry Observation|China Life Sciences And Healthcare Weekly Report No. 30

    为进一步完善全链条支持创新药发展举措,推动创新药高质量发展,更好满足人民群众多元化就医用药需求,国家医保局、国家卫生健康委联
    ChinaFood, Drugs, Healthcare, Life Sciences
    SGLA Law Firm
    SGLA Law Firm
  • Article

    China On The Move: China's Healthcare And Life Sciences Regulatory Evolution In 2025

    In the first half of 2025, China's healthcare and life sciences regulatory framework underwent a wave of important reforms. These developments reflect the country's continued efforts toward global alignment...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Greenberg Traurig
    Greenberg Traurig
  • Article

    Full Text: Joint Declaration Of The 9th ROK-Japan-China Trilateral Summit

    The following is the full text of a joint declaration of the Ninth Trilateral Summit Meeting among China, Japan and the Republic of Korea (ROK) released on Monday.
    ChinaInternational Law
    AFD China
    AFD China
  • Article

    China’s New Anti-Corruption Policies in the Health Care Industry

    On December 26 and 25, 2013, respectively, China’s National Health and Family Planning Commission (NHFPC) promulgated two circulars, Circular [2013] No. 49 (Circular 49) and Circular [2013] No. 50 (Circular 50). Circular 49, issued by NHFPC's Chinese Medicine Management Bureau, provides comprehensive anti-corruption compliance requirements to be observed by hospitals and physicians, and Circular 50 establishes a "blacklist" system on pharmaceutical and medical device providers.
    ChinaCriminal Law
    WilmerHale
    WilmerHale
  • Article

    A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

    A recent CNIPA invalidation case examines how precision medicine patents are evaluated in China, specifically addressing whether patient stratification based on biomarkers like serum alkaline phosphatase levels constitutes valid claim limitations. The decision provides critical guidance on what evidence is required to establish new patient subgroups and how disease markers must demonstrate clinical guidance value to support inventive step arguments.
    ChinaIntellectual Property
    Eagle IP
    Eagle IP
  • Showing 141–160 of 265 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics